Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2017

View Archived Issues

AmorChem Holdings spins out two new companies

Silence Therapeutics acquires equity stake in Arrowhead Pharmaceuticals

Allergan licenses rights to Assembly Biosciences' microbiome programs

FDA accepts Adaptimmune's IND for T-cell therapy targeting MAGE-A4

Vescor formed to develop autophagy therapeutics

FASN inhibitors reported in Teva patent

Chongqing University reports PDE5A inhibitors

NeuroVive, Karolinska Institutet enter collaboration for cyclophilin inhibitor

Moderna Therapeutics: developing mRNA therapeutics

Lumason obtains FDA approval for the use in ultrasonography

Servier and Vernalis jointly patent Mcl-1 inhibitors

Shionogi's cefiderocol shows positive results in cUTI study

Novartis to conduct phase II study of bimagrumab

EC approves Novo Nordisk's Fiasp for diabetes

Amgen and Immatics Biotechnologies collaborate on novel bispecific cancer immunotherapies

Bayer describes BUB1 inhibitors for cancer

Wockhardt reports antibacterial activity enhancers

Tasly Pharmaceutical describes platelet aggregation inhibitors

Crinetics Pharmaceuticals presents somatostatin receptor agonists

Update on clinical trials of dendritic cell vaccine TLP0-001

Takara Bio applies to conduct Japanese phase I/II study of CAR therapy

Protein Sciences Zika vaccine shows good safety results in preclinical studies

Phase I results from ZUMA-1 trial of KTE-C19 in patients with refractory DLBCL

MedImmune initiates phase I/Ib study of MEDI-3726 in metastatic castration-resistant prostate cancer

CRISPR Cas9 gene repair strategy shows promise for treatment of X-CGD

ViraCyte's T-cell immunotherapy wins FDA fast track, orphan designations

Heron Therapeutics submits NDA for Cinvanti in U.S.

Phase I trial explores MK-7684 alone and in combination with pembolizumab in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...